NORML Delivers Over 10,000 Public Comments To FDA Regarding International Classification Of Cannabis

DISTRICT OF COLUMBIA: NORML staffers on Wednesday hand-delivered over 10,000 public comments to the US Food and Drug Administration calling on the agency to recommend amending the substance’s illicit status under international treaties. The agency had requested public comments so that they could be “considered in preparing a response from the United States to the World Health Organization regarding the abuse liability and diversion” of marijuana and certain other substances.

NORML LOGO

It is the second time this year the FDA has sought the public’s feedback with regard to cannabis scheduling. In April, NORML staffers also delivered over 10,000 written comments to the agency from members of the public.

Writing to the FDA on NORML’s behalf, Deputy Director Paul Armentano opined “that cannabis be removed from the international drug conventions so that nations that wish to do so may further expand their regulations governing cannabis’ use, possession, production, and dispensing for either recreational or medical use.”


For more information, contact Justin Strekal, NORML Political Director, at (202) 483-5500.

 

FDA Wants To Hear Your Thoughts About CBD

DISTRICT OF COLUMBIA: The US Food and Drug Administration is soliciting public comments with regard to the therapeutic utility and abuse liability of various substances, including cannabidiol (CBD). The agency will consider these comments prior to preparing a formal response to the World Health Organization, which is considering placing the substances within their international drug scheduling code.

Cannabidiol is defined by the US Drug Enforcement Administration as a schedule I controlled substance, despite its therapeutic properties and lack of abuse potential. Seventeen states explicitly recognize CBD as a therapeutic agent by statute. Safety trials have determined the substance to be non-toxic and well-tolerated in human subjects and even the head of the US National Institute on Drug Abuse has publicly acknowledged that CBD is “a safe drug with no addictive effects.”

Those wishing to share their comments with the FDA may do so here.

The agency is accepting public comments on this topic until September 13, 2017.

For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org.